Business
Helius Medical Technologies CEO Philippe Deschamps to Deliver Congressional Briefing on the Latest Technologies, Innovations and Policies in Clinical Neuroscience
NEWTOWN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps
About this update from Solana Company
[{"type":"text","content":"NEWTOWN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”) CEO Philippe Deschamps has been invited to brief the US Congress on the latest technologies, innovations and policies in clinical neuroscience at the 9th Annual Brain Mapping Foundation Congressional briefing at the US Congress on February 25th.\n Mr. Deschamps will be presenting some thoughts on how neuromodulation can impact the outcome of Acquired Brain Injuries. “I am deeply honored to participate in this congressional briefing and thank the Brain Mapping Foundation for their invitation to participate. I am also deeply grateful for the commitment of Congress to discuss this very important topic,” said Deschamps. “With the high unmet medical need for innovative treatments for neurological conditions it is encouraging that the private and public sector are joining forces to help these people in need,” continued Deschamps. About Helius Medical Technologies, Inc. Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com. About the PoNS™ Device and PoNS Treatment™ The Portable Neuromodulation Stimulator (PoNS™) is an authorized class II, non-implantable, medical device in Canada intended for use as a short term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union (“EU”), and Australia (“AUS”), and it is currently under review for clearance from the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia. About the Society for Brain Mapping and Therapeutics Foundation The Society for Brain Mapping and Therapeutics (SBMT) is a non-profit society organized for the purpose of encouraging basic and clinical scientists who are interested in areas of Brain Mapping, engineering, stem cell, nanotechnology, imaging and medi...